Income Statement
PROCESSA PHARMACEUTICALS, INC.
PCSA
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - | - | - | - | 0.01 | 0.11 | 0.20 | 0.31 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - | - | - | - | 0.01 | -0.01 | 0.09 | 0.09 |
|
Operating Expenses
|
6.18 | 4.78 | 5.66 | 8.76 | 4.69 | 6.44 | 3.94 | 4.52 | 1.80 | 0.08 | 2.68 | 4.25 | 3.09 |
|
Research & Development
|
7.81 | 7.27 | 5.80 | 11.49 | 6.88 | 3.17 | 2.32 | 3.09 | - | 0.01 | 0.03 | 0.19 | 0.27 |
|
Selling, General & Administrative
|
6.18 | 4.78 | 5.66 | 8.76 | 4.69 | 3.26 | 1.61 | 1.44 | - | 0.07 | 0.95 | 2.84 | 2.82 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-6.18 | -4.78 | -5.66 | -8.76 | -4.69 | -6.44 | -3.94 | -4.52 | -1.80 | -0.07 | -2.69 | -4.16 | -3.00 |
|
Non-Operating Income
|
7.39 | 7.07 | 5.46 | 18.66 | 7.27 | 8.98 | 0.03 | 0.14 | - | 0.27 | 0.29 | 0.37 | 0.07 |
|
Interest Income
|
0.11 | 0.20 | 0.34 | 0.10 | 0.01 | 0.00 | 0.01 | 0.02 | 0.01 | - | 0.00 | 0.00 | 0.00 |
|
Interest Expense
|
- | - | - | - | 0.00 | 0.28 | 0.04 | 0.16 | 0.17 | 0.25 | 0.24 | -0.37 | -0.11 |
|
Other Non-Op Income / Expense
|
0.42 | - | - | - | - | - | - | - | - | - | - | - | - |
|
Income Before Tax
|
-13.56 | -11.85 | -11.12 | -27.42 | -11.96 | -15.41 | -3.96 | -4.67 | - | -0.34 | -2.98 | -4.53 | -3.07 |
|
Income Tax Expense
|
0.00 | 0.00 | 0.00 | 0.00 | -0.53 | -1.00 | -0.60 | -0.90 | - | 0.00 | 0.37 | 0.00 | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-13.56 | -11.85 | -11.12 | -27.42 | -11.43 | 15.90 | 4.85 | 3.77 | -1.86 | -0.34 | -3.35 | -4.53 | -3.07 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-6.18 | -4.78 | -5.66 | -8.76 | -4.69 | -6.44 | -3.94 | -4.52 | -1.80 | -0.07 | -2.69 | -4.16 | -3.00 |
|
Earnings Per Share (Basic)
|
-10.36 | -3.87 | -8.48 | -1.70 | - | - | - | - | -0.06 | - | - | - | - |
|
Diluted EPS
|
-10.36 | -3.87 | -8.48 | - | - | - | - | - | -0.06 | - | - | - | - |
|
Weighted Average Shares
|
1.31 | 3.06 | 1.31 | 16.11 | - | - | - | - | 32.60 | - | - | - | - |
|
Diluted Weighted Avg Shares
|
1.31 | 3.06 | 1.31 | - | - | - | - | - | 32.60 | - | - | - | - |
|
Comprehensive Income
|
- | - | - | - | - | - | - | - | - | - | - | - | - |